Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902928 | 0.78 | GPR35 (0.47) | GPR35DAOXDHSLC22A12CSNK2A2 | |
| SCHEMBL3238461 | 0.74 | CA1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3936083 | 0.73 | LDHA (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2971000 | 0.71 | CA1 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29419955 | 0.71 | CA1 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20562476 | 0.69 | POLB (0.42) | CSNK2A1KDM4EMAPTGAAALDH1A1 | |
| SCHEMBL20562338 | 0.69 | ESR1 (0.35) | KDM4EMAPTGAAALDH1A1HTT | |
| SCHEMBL20563419 | 0.69 | MAPT (0.42) | KDM4EMAPTGAAALDH1A1HTT | |
| SCHEMBL10934474 | 0.69 | MAPT (0.34) | KDM4EMAPTGAAALDH1A1HTT | |
| SCHEMBL3483612 | 0.69 | CYP3A4 (0.39) | KDM4EMAPTGAAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334095-B1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1334095-A4 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2004-03-17 | — | — | EP | claimed |
| US-6693203-B2 | REACTING NOPINONE ENOLATE WITH ALKYL 7-HALO-5-HEPTYNOATE, REACTING PRODUCT WITH HYDROXYLAMINE, TREATING WITH TITANIUM TRICHLORIDE AND BORANE REAGENT, HYDROGENATING, REACTING WITH 5-HYDROXY-4-BENZOTHIOPHENECARBOXYLIC ACID, HYDROLYZING | SHIONOGI & CO., LTD (JP) | 2004-02-17 | — | — | US | claimed |
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | LARSEN ROBERT (US) | 2003-10-23 | — | — | US | claimed |
| EP-1334095-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2003-08-13 | — | — | EP | claimed |
| WO-2002032892-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD (JP) | 2002-04-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | PTGDR, PTGDR2, PTGER2 | CA12 4865/4885CA1 4720/4885CA2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.